Claton L, Baker C, Martin H, Dzyuba S, Zaman K, Prokai L
Biomolecules. 2025; 14(12.
PMID: 39766332
PMC: 11726873.
DOI: 10.3390/biom14121625.
Ma C, Xu J, Wang X, Wang X, Zhang L, Jing S
RSC Adv. 2024; 14(49):36754-36762.
PMID: 39559574
PMC: 11571120.
DOI: 10.1039/d4ra05923a.
Burggraef M, Oxley A, Zaidi N, Cutillas P, Gaffney P, Livingston A
Nat Commun. 2024; 15(1):9814.
PMID: 39537591
PMC: 11560933.
DOI: 10.1038/s41467-024-54076-6.
Khan M
Polymers (Basel). 2024; 16(18).
PMID: 39339093
PMC: 11435517.
DOI: 10.3390/polym16182629.
Sun Q, Gao H, Liu Y, Wang L, Huang J
Heliyon. 2024; 10(16):e36210.
PMID: 39224279
PMC: 11367462.
DOI: 10.1016/j.heliyon.2024.e36210.
Coupling enterotoxigenic Escherichia coli heat-stable peptide toxin with 8-arm PEG enhances immunogenicity.
Zegeye E, Chaukimath P, Diaz Y, Visweswariah S, Puntervoll P
J Pept Sci. 2024; 31(1):e3647.
PMID: 39091086
PMC: 11602266.
DOI: 10.1002/psc.3647.
Efficacy and safety of visepegenatide, a long-acting weekly GLP-1 receptor agonist as monotherapy in type 2 diabetes mellitus: a randomised, double-blind, parallel, placebo-controlled phase 3 trial.
Yan X, Ma J, Liu Y, Wang X, Li S, Yan S
Lancet Reg Health West Pac. 2024; 47:101101.
PMID: 38948164
PMC: 11214404.
DOI: 10.1016/j.lanwpc.2024.101101.
Research progress on the PEGylation of therapeutic proteins and peptides (TPPs).
Li C, Li T, Tian X, An W, Wang Z, Han B
Front Pharmacol. 2024; 15:1353626.
PMID: 38523641
PMC: 10960368.
DOI: 10.3389/fphar.2024.1353626.
Stabilizing Scaffold for Short Peptides Based on Knottins.
Beloborodov E, Iurova E, Sugak D, Rastorgueva E, Pogodina E, Fomin A
Curr Cancer Drug Targets. 2024; 24(12):1275-1285.
PMID: 38357956
DOI: 10.2174/0115680096285288240118090050.
Reducing Immunogenicity by Design: Approaches to Minimize Immunogenicity of Monoclonal Antibodies.
Harris C, Cohen S
BioDrugs. 2024; 38(2):205-226.
PMID: 38261155
PMC: 10912315.
DOI: 10.1007/s40259-023-00641-2.
Lipidization as a tool toward peptide therapeutics.
Myskova A, Sykora D, Kunes J, Maletinska L
Drug Deliv. 2023; 30(1):2284685.
PMID: 38010881
PMC: 10987053.
DOI: 10.1080/10717544.2023.2284685.
A Dual-Enzyme Amplification Loop for the Sensitive Biosensing of Endopeptidases.
Zhou C, Li X, Tang S, Liu C, Lam M, Lam Y
ACS Omega. 2023; 8(28):25592-25600.
PMID: 37483190
PMC: 10357553.
DOI: 10.1021/acsomega.3c03533.
Self-assembling and pH-responsive protein nanoparticle as potential platform for targeted tumor therapy.
Xu Z, Zhang X, Dong W, Lv H, Zuo L, Zhu L
Front Mol Biosci. 2023; 10:1172100.
PMID: 37234918
PMC: 10206137.
DOI: 10.3389/fmolb.2023.1172100.
Design and Application of Hybrid Polymer-Protein Systems in Cancer Therapy.
Sun Q, Yang Z, Qi X
Polymers (Basel). 2023; 15(9).
PMID: 37177365
PMC: 10181109.
DOI: 10.3390/polym15092219.
Hybrid Silica-Coated PLGA Nanoparticles for Enhanced Enzyme-Based Therapeutics.
Gustafson K, Mokhtari N, Manalo E, Montoya Mira J, Gower A, Yeh Y
Pharmaceutics. 2023; 15(1).
PMID: 36678770
PMC: 9866096.
DOI: 10.3390/pharmaceutics15010143.
Motif-based zwitterionic peptides impact their structure and immunogenicity.
McMullen P, Qiao Q, Luozhong S, Cai L, Fang L, Shao Q
Chem Sci. 2022; 13(36):10961-10970.
PMID: 36320710
PMC: 9491220.
DOI: 10.1039/d2sc03519g.
Recent and future perspectives on engineering interferons and other cytokines as therapeutics.
Aung T, Grubbe W, Nusbaum R, Mendoza J
Trends Biochem Sci. 2022; 48(3):259-273.
PMID: 36241490
PMC: 9974544.
DOI: 10.1016/j.tibs.2022.09.005.
S100 Proteins as Novel Therapeutic Targets in Psoriasis and Other Autoimmune Diseases.
Kurpet K, Chwatko G
Molecules. 2022; 27(19).
PMID: 36235175
PMC: 9572071.
DOI: 10.3390/molecules27196640.
The current research status and strategies employed to modify food-derived bioactive peptides.
Majura J, Cao W, Chen Z, Htwe K, Li W, Du R
Front Nutr. 2022; 9:950823.
PMID: 36118740
PMC: 9479208.
DOI: 10.3389/fnut.2022.950823.
Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma.
Maese L, Rau R
Front Pediatr. 2022; 10:902117.
PMID: 35844739
PMC: 9279693.
DOI: 10.3389/fped.2022.902117.